Sigma Planning Corp lessened its stake in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY – Free Report) by 49.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,635 shares of the company’s stock after selling 49,800 shares during the quarter. Sigma Planning Corp owned approximately 0.13% of Brainsway worth $668,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Masters Capital Management LLC lifted its stake in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after acquiring an additional 650,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Brainsway by 87.2% in the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after acquiring an additional 241,560 shares in the last quarter. Y.D. More Investments Ltd grew its stake in shares of Brainsway by 136.6% in the 1st quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock worth $3,615,000 after acquiring an additional 157,042 shares in the last quarter. HWG Holdings LP bought a new stake in shares of Brainsway in the 3rd quarter worth $3,340,000. Finally, Sei Investments Co. raised its holdings in shares of Brainsway by 262.5% in the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after purchasing an additional 163,925 shares during the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.
Brainsway Stock Down 4.8%
Shares of NASDAQ BWAY opened at $11.36 on Friday. The firm has a market cap of $457.24 million, a P/E ratio of 27.11 and a beta of 1.29. The company has a 50 day moving average of $12.95 and a 200 day moving average of $13.93. Brainsway Ltd. Sponsored ADR has a twelve month low of $7.14 and a twelve month high of $17.40.
Brainsway (NASDAQ:BWAY – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. Brainsway had a return on equity of 12.74% and a net margin of 15.65%. The company had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.54 million. As a group, equities analysts expect that Brainsway Ltd. Sponsored ADR will post 0.33 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently weighed in on BWAY shares. New Street Research restated a “buy” rating on shares of Brainsway in a research report on Friday, July 24th. HC Wainwright restated a “buy” rating on shares of Brainsway in a research report on Friday. BTIG Research reaffirmed a “buy” rating and set a $20.00 price objective on shares of Brainsway in a report on Thursday, September 10th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Finally, Weiss Ratings lowered shares of Brainsway from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Brainsway presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.20.
Check Out Our Latest Stock Analysis on Brainsway
About Brainsway
BrainsWay Ltd. (NASDAQ: BWAY) is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses a helmet-like device to deliver magnetic stimulation to targeted areas of the brain.
The company’s Deep TMS systems are used in the treatment of major depressive disorder and obsessive-compulsive disorder, and have also received regulatory clearances for certain additional indications, including smoking cessation.
Read More
- Five stocks we like better than Brainsway
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
